New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
12:00 EDTRLYPRelypsa rises 10.6%
Relypsa is up 10.6%, or $4.64, to $48.55
News For RLYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
15:31 EDTRLYP5AM Ventures III lowers stake in Relypsa to 5.89% from 9.38%
Subscribe for More Information
March 26, 2015
19:04 EDTRLYPRelypsa Phase 3 data says Patiromer FOS prevents recurrence of hyperkalemia
Relypsa announced that data from a Phase 3 clinical program showing that Patiromer for Oral Suspension, or Patiromer FOS, the company's lead product candidate, was effective in reducing potassium levels and preventing a recurrence of hyperkalemia in patients with advanced chronic kidney disease receiving ongoing treatment with renin-angiotensin-aldosterone system inhibitors were presented as a poster at the National Kidney Foundation 2015 Spring Clinical Meeting. The results are from a sub-group analysis of the two part Phase 3 trial, OPAL-HK, conducted under a Special Protocol Assessment with the FDA that was led by Matthew Weir, M.D., Professor and Director, Division of Nephrology, University of Maryland School of Medicine. The Phase 3 OPAL-HK trial primary outcomes, previously published in the New England Journal of Medicine, were combined with results from Relypsa's broader clinical development program to support the company's New Drug Application, or NDA, for Patiromer FOS. The FDA has assigned a Prescription Drug User Fee Act, or PDUFA, action date of October 21 for completion of the review of the NDA.
March 15, 2015
13:51 EDTRLYPRelypsa announces Phase 2 Data showing efficacy of Patiromer FOS in HF patients
Relypsa announced that one year data showing the safety and efficacy of Patiromer for Oral Suspension-Patiromer FOS, Relypsa's lead product candidate, in heart failure, HF, patients with hyperkalemia receiving ongoing treatment with renin-angiotensin-aldosterone system, RAAS, inhibitors will be presented today as a poster at the American College of Cardiology 64th Annual Scientific Session. The poster data is a sub-group analysis of a multi-center, randomized, open-label Phase 2 trial, AMETHYST-DN, led by Bertram Pitt, M.D., Professor of Medicine, Emeritus, University of Michigan School of Medicine. In addition, Relypsa is sponsoring an industry panel to review the latest data in the management of hyperkalemia, led by Ileana L. Piņa, MD, Professor of Medicine and Epidemiology & Population Health at Albert Einstein College of Medicine. The U.S. Food and Drug Administration assigned a Prescription Drug User Fee Act, PDUFA, action date of October 21 for completion of the review of the New Drug Application, NDA, for Patiromer FOS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use